Deep Response to IL‑13 and IL‑4/13 Inhibition in AD

0 SAR
Checkout

Overview

A concise scientific overview of deep and sustained treatment response in moderate‑to‑severe atopic dermatitis, highlighting the clinical impact of IL‑13 and IL‑4/13 pathway inhibition.


This Class for

  • Physician
  • Resident / Fellow

What I will learn?

    • Define deep and sustained response in moderate‑to‑severe atopic dermatitis.
    • Highlight the role of IL‑13 and IL‑4/13 pathways in disease control.
    • Understand the clinical rationale for targeting IL‑13 and IL‑4/13 in AD management.

     


    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com

    24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com

    For further information, please contact:

    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com
    Please go to PDF Material for prescribing information.

    PP-LK-SA-0195


Related Classes